Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase II Efficacy and Safety Study of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis
Sponsor: Haisco Pharmaceutical Group Co., Ltd.
Summary
The purpose of this study is to assess the efficacy and safety of HSK44459 administered orally for moderate to severe plaque psoriasis in adults.
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HSK44459 in Subjects With Moderate to Severe Plaque Psoriasis
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2025-09-26
Completion Date
2026-11-06
Last Updated
2025-09-02
Healthy Volunteers
No
Conditions
Interventions
HSK44459 dose level 1
HSK44459 dose level 1 oral administration
HSK44459 dose level 2
HSK44459 dose level 2 orally administration
placebo
placebo oral adminisitration
Locations (1)
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China